Show simple item record

dc.contributor.authorChalkidou, Kalipso
dc.contributor.authorTowse, Adrian
dc.contributor.authorSilverman, Rachel
dc.contributor.authorGarau, Martina
dc.contributor.authorRamakrishnan, Ganesh
dc.date.accessioned2020-05-27T04:55:56Z
dc.date.available2020-05-27T04:55:56Z
dc.date.issued2020
dc.identifier.issn2059-7908
dc.identifier.doi10.1136/bmjgh-2019-002061
dc.identifier.urihttp://hdl.handle.net/10072/394190
dc.description.abstractSummary box: - Tuberculosis (TB) is the world’s deadliest infectious disease; without a significant technological breakthrough, current trajectories suggest that the world will not achieve the Convergence 2035 targets for TB until 2074, almost 40 years later than originally projected. - Research and development investments for TB are dominated by public sources and total only one-third of estimated need, with private investment small and declining. - To crowd in private investment, we suggest a new model—the market-driven,value-based advance commitment (MVAC)—wherein high-burden middle-income countries (MICs) would offer advanced purchase commitments for a prespecified breakthrough treatment regimen. - Through use of early health technology assessment, an emerging practice and capability in many large MICs, the MVAC would ensure that country purchase commitments reflect local needs, value and ability to pay for innovation. - A multilateral development bank would underwrite the MVAC commitments, increasing their credibility to private industry without requiring countries to put aside funds in advance. - Discussion with developing country policymakers, industry, development banks and development partners suggest fertile ground for the MVAC approach, but high-level political commitment is still needed.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofpagefrome002061:1
dc.relation.ispartofpagetoe002061:6
dc.relation.ispartofissue4
dc.relation.ispartofjournalBMJ Glob Health
dc.relation.ispartofvolume5
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchHealth Economics
dc.subject.fieldofresearchcode1117
dc.subject.fieldofresearchcode140208
dc.subject.keywordshealth policies and all other topics
dc.subject.keywordshealth systems evaluation
dc.subject.keywordsinfections, diseases, disorders, injuries
dc.subject.keywordstuberculosis
dc.titleMarket-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationChalkidou, K; Towse, A; Silverman, R; Garau, M; Ramakrishnan, G, Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB., BMJ Glob Health, 2020, 5 (4), pp. e002061:1-e002061:6
dcterms.dateAccepted2020-02-28
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2020-05-27T04:43:22Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
gro.hasfulltextFull Text
gro.griffith.authorChalkidou, Kalipso


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record